Multiple sclerosis (MS) affects about 700,000 people in Europe, of whom around 96,000 suffer from the progressive primary form, which causes major disabilities. Most people diagnosed with MS suffer from recurrent (RMS) or primary progressive (PPMS) form at the time of diagnosis.
Until this drug, people suffering from primary-progressive multiple sclerosis (PPMS), who often had to move with a cane or wheelchair, quit their jobs and require special care, did not have approved treatments to slow the progression of the disease. People with recurrent-remissive multiple sclerosis (MS) often had to choose between increased safety and efficacy of treatment. This drug is given once every six months, without the need for constant monitoring, which, we hope, will help people live their lives without thinking about treatment on a daily basis, “said Gavin Giovannoni, Professor of Neurology at Barts. and London School of Medicine and Dentistry, Queen Mary University of London.
The drug has major benefits for patients suffering from multiple sclerosis Primary progressive in the early stages, is an important option for those suffering from recurrent forms of multiple sclerosis and is produced by Roche.
Photo: pixabay.com
–
